导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.68% | 1547/4773 |
| 近一周 | -1.98% | 1003/5462 |
| 近一月 | -3.03% | 1516/5421 |
| 近一季 | -6.53% | 2128/5209 |
| 近半年 | -0.07% | 1224/4920 |
| 近一年 | 6.34% | 1473/4366 |
| 近两年 | 50.39% | 1450/2954 |
| 近三年 | 31.48% | 994/2253 |
| 成立以来 | 220.10% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.96% 2582/4961 |
14.48% 1808/5312 |
- - |
- - |
| 2025 | 20.86% 2079/4813 |
- 2014/3635 |
2.10% 1869/4076 |
16.32% 2670/4524 |
1.77% 1226/4813 |
| 2024 | 13.00% 1192/3463 |
2.48% 771/2808 |
-1.31% 1034/3014 |
14.38% 1983/3129 |
-2.32% 2041/3463 |
| 2023 | -9.94% 1249/2656 |
2.28% 1385/2280 |
-3.68% 860/2385 |
-3.02% 826/2515 |
-5.74% 1483/2655 |
| 2022 | -20.96% 1004/2207 |
-11.89% 553/1919 |
3.54% 1135/2016 |
-11.79% 584/2113 |
-1.78% 1738/2208 |
| 2021 | -2.61% 862/1822 |
0.79% 277/1255 |
4.75% 849/1330 |
-6.47% 935/1466 |
-1.38% 1360/1822 |
| 2020 | 28.07% 567/1250 |
-8.97% 644/1028 |
14.44% 552/1067 |
12.35% 391/1164 |
9.43% 641/1184 |
| 2019 | 34.98% 385/1092 |
26.27% 417/754 |
0.83% 154/804 |
1.02% 436/850 |
4.95% 763/918 |
| 2018 | -23.46% 281/834 |
- - |
- - |
- - |
-12.73% 478/691 |
| 2017 | 33.63% 44/714 |
- - |
- - |
- - |
- - |
| 2016 | -0.69% 110/605 |
- - |
- - |
- - |
- - |
| 2015 | 18.98% 123/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 景顺长城沪深300指数增强A VS. 长安沪深300非周期A(740101) |